Topic Forum 3 - Adenocarcinomas slightly above, slightly below and within the gastroesophageal junction: what are their specific sites of origin, and how can we tell? [ ]

Product 35 of 39

From: Sessions

Topic Forum 3 - Adenocarcinomas slightly above, slightly below and within the gastroesophageal junction: what are their specific sites of origin, and how can we tell?

$10.00

Select Format:

Includes all of these presentations from this session:

# Presentation Speaker

1 Are there differences between carcinomas arising in all these areas? By clinical features? A. Chang (Ann Arbor)

2 Are there differences between carcinomas arising in all these areas? By gross feature? J. Gibson (New Haven)

3 Are there differences between carcinomas arising in all these areas? Histologically? X. Sagaert (Leuven)

4 Are there differences between carcinomas arising in all these areas? By immunohistochemistry? M. Upton (Seattle)

5 How does the endoscopist tell? J.M. Inadomi (Seattle)

6 How does the surgeon tell? G. Darling (Toronto)

7 How does the pathologist tell? From biopsies? G. Soucy (Montreal)

8 How does the pathologist tell? From EMR specimens? A. Grin (Toronto)

9 How does the pathologist tell? From resection specimens D. Jain (New Haven)

10 How does the pathologist tell? From resection specimens following neoadjuvant therapy? R. Langer (Bern)

11 What are the possible precursors of adenocarcinomas in the region of the cardia? Helicobacter H. El-Zimaity (Toronto)

12 What are the possible precursors of adenocarcinomas in the region of the cardia? Foveolar mucosa R.K. Yantiss (New York)

13 What are the possible precursors of adenocarcinomas in the region of the cardia? Intestinal metaplasia limited to the cardia V. Villanacci (Brescia)

14 What are the possible precursors of adenocarcinomas in the region of the cardia? Esophageal pyloric gland adenomas M. Tripathi (Toronto)

15 What are the possible precursors of adenocarcinomas in the region of the cardia? Pancreatic metaplasia S. Al-Haddad (Toronto)

16 Is there any reason to make these distinctions in site of origin? Therapeutically A. Chang (Ann Arbor)

17 Is there any reason to make these distinctions in site of origin? Prognostically R. Langer (Bern)

18 Is there any reason to make these distinctions in site of origin? Her2 immunoreactivity C. Streutker (Toronto)

19 Is there any reason to make these distinctions in site of origin? Response to Herceptin G. Darling (Toronto)